Lucid Appoints Telemedicine Executive Matthew Cox to Board of Directors

ROCHESTER, N.Y.--(BUSINESS WIRE)--Lucid, Inc., the leader in FDA approved noninvasive cellular imaging, today announced that Matthew C. Cox, has been appointed to the Company’s Board of Directors. Mr. Cox brings to Lucid a wealth of experience in telemedicine, and currently serves as Vice President of vRad, the world’s leading teleradiology firm. His appointment increases the size of the Lucid Board to eight.

“Matt is a practical and results-oriented executive who has played a key management role in helping build the world’s leading teleradiology company”

“I’m delighted to join Lucid’s Board as it begins the rollout of its FDA-cleared VivaScope^® imaging technology and its VivaNet^® telepathology system into private dermatology and dermatopathology practices. The combination of these two technologies can lower costs and reduce time-to-diagnosis for patients with suspicious skin lesions,” said Mr. Cox. “Lucid’s proprietary technologies provide a unique and enormous business opportunity in the telepathology space. I look forward to working with the Lucid management team to solidify noninvasive confocal imaging into the mainstream of dermatopathology.”

Throughout his career, Mr. Cox has developed and implemented corporate strategies from business concepts through deployment, improved product revenue, profit margins and competitiveness, developed new business models and led product development teams. Prior to vRad he was Director of Enterprise Solutions at Misys Healthcare, where he was responsible for Misys enterprise-level products and customers. As administrator for Duke University Health System and a practice management/accounting consultant, Mr. Cox assisted physicians and practices maximize performance in operations, revenue growth and issues related to billing and compliance. He holds a B.S. in Medical Humanities at Davidson College in Charlotte, N.C.

“Matt brings with him deep knowledge and experience that is directly relevant to Lucid,” said William Shea, Chairman of the Board of Directors at Lucid. “Specifically, Matt’s experiences in the critical real-world issues of running a telemedicine company and dealing with medical reimbursement and billing will be important assets to Lucid.”

“Matt is a practical and results-oriented executive who has played a key management role in helping build the world’s leading teleradiology company,” said Jay Eastman, CEO of Lucid. “Lucid has established itself as the leader in accurate, noninvasive assessment and diagnosis of melanoma and other skin cancers. The experience and track record that Matt brings to Lucid’s Board will greatly assist the management team in rapidly driving adoption of our platform to the benefit of patients, dermatologists, pathologists and ultimately our employees and shareholders.”

About Lucid, Inc.

Lucid, Inc. is the leader in, noninvasive skin cancer imaging and diagnosis through the use of its FDA cleared VivaScope^® confocal imagers and its innovative VivaNet^® telepathology system that allows secure, HIPAA compliant, near real-time collaboration between dermatologists and pathologists. VivaNet^® provides rapid online medical image transfer storage and retrieval, enabling critical collaborative consultations at the point and time of care. Lucid’s VivaScopes^® provide images that physicians can use to form critical medical decisions in cases of melanoma and other skin cancers while ensuring patient comfort and piece of mind. You can learn more about the Company and its innovative products at www.lucid-tech.com.

VivaScope^® and VivaNet^® are registered trademarks of Lucid, Inc.